Eligibility for duty-free treatment under Nairobi Protocol concerning the Neria™ Guard Infusion Set from Denmark.
No Headquarters ruling in this index revokes or modifies this ruling. That is not confirmation that it is still in effect: this index does not hold every Headquarters ruling. Confirm its current status with CBP before relying on it (ruling on CBP CROSS). Text last read from CBP on Nov 21, 2026.
Ruling text
In your letter dated April 23, 2026 , you requested a tariff classification ruling on behalf of Convatec, Inc.The Neria™ Guard Infusion Set is a subcutaneous system for continuous medication delivery via a portableinfusion pump. It features flexible tubing in various lengths, a connector for secure pump attachment, and asoft cannula at the patient end for insertion under the skin. Secure adhesive fixation and anti-kink tubingsupport patient-managed therapy in home and ambulatory settings.
Designed exclusively for subcutaneoususe, it is not suitable for intravenous infusion and is ideal for long-term treatment of chronic conditionsoutside hospital environments.Neria™ Guard infusion sets are prescription medical devices distributed through specialized channels andrequire authorization from a licensed healthcare provider.
They are primarily used for continuoussubcutaneous infusion therapies to treat chronic conditions such as Parkinson’s disease and PulmonaryArterial Hypertension (PAH), with about 95% of usage associated with these patients. The sets are used inconnection with FDA-approved prescription medications, including Vyalev (foslevodopa/foscarbidopa) andOnapgo (apomorphine hydrochloride), which address motor fluctuations in adults with advanced Parkinson’sdisease.
Both Parkinson’s disease and PAH are chronic, progressive conditions requiring ongoing treatment.Parkinson’s disease is a chronic, progressive neurological disorder marked by motor impairment such astremors, rigidity, and difficulty with movement. PAH is a chronic, life-threatening condition in which affectsthe pulmonary arteries, resulting in significant limitation on breathing, physical exertion, and overallfunctional capacity.
In your submission you requested consideration of a secondary classification under 9817.00.96, HarmonizedTariff Schedule of the United Sates (HTSUS), which applies to articles and parts and accessories of articlesspecifically designed or adapted for the use or benefit of the permanently or chronically physically ormentally handicapped.Subheading 9817.00.96, HTSUS, covers: “Articles specially designed or adapted for the use or benefit of theblind or other physically or mentally handicapped persons; parts and accessories (except parts andaccessories of braces and artificial limb prosthetics) that are specially designed or adapted for use in theforegoing articles . . .
Other.” The term “blind or other physically or mentally handicapped person includes“any person suffering from a permanent or chronic physical or mental impairment which substantially limitsone or more major life activities, such as caring for one’s self, performing manual tasks, walking, seeing,hearing, speaking, breathing, learning, or working.” U.S. Note 4(a), Subchapter XVII, Chapter 98, HTSUS.Subheading 9817.00.96, HTSUS, excludes “(i) articles for acute or transient disability; (ii) spectacles,dentures, and cosmetic articles for individuals not substantially disabled; (iii) therapeutic and diagnosticarticles; or, (iv) medicine or drugs.” U.S. Note 4(b), Subchapter XVII, Chapter 98, HTSUS.In Sigvaris, Inc. v. United States, 227 F. Supp 3d 1327, 1336 (Ct.
The text above is an excerpt. The official ruling, with its letterhead, signature and any attachments, is on CBP CROSS (N360966).